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Introduction
Acute myeloid leukemia (AML) is a clonal disease cha-
racterized by the proliferation and accumulation of 
myeloid progenitor cells in bone marrow, which ulti-
mately leads to hematopoietic failure.1,2 The inciden-
ce of AML increases with age, and older patients ty-
pically have worse treatment outcomes than younger 
patients.3 Diagnosis of AML is based on cellular morpho-
logy, immunology, cytogenetics, and molecular features.4 
 
A number of prognostic factors have been identified 
in AML, including age, performance status, organ dys-
function, secondary AML, white blood cell and blast 
count at presentation, karyotype, and molecular ab-
normalities.5,6 Most relevant studies, based on large 
multicenter trials have definitively demonstrated that 
age and cytogenetics at diagnosis are the most signi-
ficant prognostic determinants for patients with AML.7 
 
This study focuses on survival rate, prognostic factors and 
the evolution of AML in patients. The purpose of this stu-
dy was to formulate an Assessment Scheme for Prognosis 
of AML. Even if these prognostic factors were previously 
studied our goal was to develop a score, which is easy 
to calculate, for early prognostic assessment at diagnosis. 
Especially in Romania or other less-highly developed cou-
ntries, this scheme would be beneficial particularly when 
cytogenetic testing is unavailable or time-intensive.
Methods
We performed a retrospective longitudinal study on 119 
patients, aged 21-85 years with a median age of 60. Using 
statistical tests such as Excel and Epi Info we managed to 
associate, analyze and compare the variables. Additionally, 
this study was analytical and observational.
The length of the study was five years, from January 2007 
to November 2011. The main feature of all patients was the 
presence of AML. The demographic characteristics included 
the patients admitted at the Department of Hematology 
of the Oncology Institute “Prof. Dr. Ion Chiricuta”, Cluj-
Napoca, Romania. Although it was a single-center study, it 
comprised a whole region of Romania, because Cluj-Napoca 
is the most important medical centre in Transilvania.
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We aimed to identify the most important prognostic factors, 
therefore to perform a risk assessment for patient with 
AML. According to Kaplan-Meier’s method, we analysed the 
patient’s survival rate to illustrate the differences between 
specific variables and the characteristics of the patients.
 
We formulated five research hypotheses, which confirmed 
a shorter survival for 60 year olds, secondary AML patients, 
patients with severe comorbidities and patients with 
elevated levels of WBC and blasts.
The data used in the study comprised: gender, age, place 
of origin, date of admission, FAB type, WHO classification, 
cytogenetic examination, immunophenotyping, laboratory 
data (hemoglobin, erythrocytes, leukocytes, platelets, 
LDH, blasts), symptoms, comorbidity, other malignancies, 
dysplasia, treatment, complications, date of death and 
status censorship. Status of censorship coding included 
two groups of patients. The first group was “censored” if 
at the end of study, some patients were lost, whereas the 
second group was “complete” if during the study, some 
patients died.
Results
Histogram of the age intervals was significantly high among 
patients over 50 year old (77%). In addition, 34 patients 
were included in the 50-59 years interval, followed by 31 
cases in the sixth decade interval and 27 cases included in 
the seventh decade until the age of 85 years. In Figure 1 we 
represented a statistical test conducted in Epi Info, where 
all patients were divided in two groups: group A1 <60 year 
olds and group B1 ≥60 year olds. Consequently, the group 
A1 achieved a survival of 40 months and group B1 a 19 
month survival (p=0,0063).
Almost 14% presented with other malignancies requiring 
radio-chemotherapy. As a result, patients with these 
malignancies developed secondary AML. Moreover, half of 
all cancer patients presented with genitourinary malignancy 
whilst a third were gastrointestinal in origin. Analysis of the 
survival of primary and secondary AML patients revealed 
significant differences. As shown in Figure 2, there was a 
15 month survival for the first group (A2 =Secondary AML) 
and 40 month survival for the last group (B2 =AML de novo, 
p=0,0021).
Figure 1. Survival probability according to age Group A1 <60years (red) and 
Group B1 ≥60years (green)
Figure 2. Survival probability according to presence of secondary AML, Group 
A2 with Secondary AML (red) and Group B2 with AML de novo (green)
Figure 3. Survival probability according to comorbidity, Group A3 with mild 
comorbidity (red), Group B3 with moderate comorbidity (green) and Group 
C3 with severe comorbidity (pink)
Figure 4. Survival probability according to level of WBC and Blasts, Group 
A4= WBC <15.000/mm3 + blasts <40% (red) and Group B4= WBC >15.000/mm3 
+ blasts >40% (green)
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A proportion of 64% of cases had associated comorbidities 
as they were present especially within the elderly patients. 
The most frequent were the heart diseases, which 
comprised 60 cases. Digestive and respiratory illnesses 
ranked next with 28 and 21 cases respectively. The next 
frequent disease was diabetes with 19 cases and the less 
frequent diseases were renal and neurological disorders 
with 10 and 9 cases respectively. We separated patients, 
according to comorbidities into three groups seen in Figure 
3. Group A3 comprised patients with mild comorbidity with 
a survival of 40 months. Group B3 covered patients with 
moderate comorbidities who survived 19 months, whereas 
group C3 included patients with serious comorbidities who 
survived only 7 months (p=0,0059).
As shown in the Figure 4, in Epi Info, we analyzed two 
categories: group A4 =WBC <15.000/mm3 + blasts <40% and 
group B4 =WBC >15.000/mm3 + blasts >40%. Survival in 
group A4 was up to 40 months, whereas the group B4 had 
a survival of 25 months (p=0,0057).
Only 26% of patients received cytogenetic examination. 
The prognosis distribution of results followed the WHO 
classification, therefore 71% of patients correspond to 
intermediate risk, whereas 29% of patients correspond to 
unfavorable risk with chromosomal abnormalities (Figure 5). 
Discussion
Various clinical and biological features identified previously 
as useful factors in the prediction of clinical outcomes, could 
help guide therapy choices.8 Large multicenter trials have 
demonstrated that: patient’s age, presence of secondary 
AML, WBC count, cytogenetic and comorbidities at diagnosis 
were important prognostic factors for AML patients.9
Age remained one of the most significant prognostic 
factors and its importance has increased among the elderly 
population.10 Our study shows a clear difference of survival 
period between the two age groups: <60, >60 years. We 
decided to define a 60 year-limit because this age is the 
limit between adults and elderly people. We were not able 
to find the sample size variable due to the small number of 
patients. We recognized age as a vital prognostic factor in 
AML, so we included it in our prognosis scheme.
We highlighted the importance of prior malignancies and 
their treatment that had a major impact on our patients 
survival rate.11 Furthermore, patients with previous 
malignancies developed secondary AML, which in our 
study illustrated a surprisingly low life expectancy. As a 
result, patients with AML de novo lived twice as long as the 
patients with secondary AML. 
Comorbidities affect the therapeutic plan and the post-
therapeutic outcome of the index disease. Examples 
include patients with cancer and multiple studies 
have demonstrated the relevance of comorbidities in 
prognosis.12,13 Consequently, we stratified comorbidities 
after the Sorror Comorbidity Index in mild, moderate and 
severe comorbidities. Kaplan-Meier survival illustrated a 
significant difference between the groups in our study. As 
a result, comorbidities are an important prognostic factor, 
which affects the survival of patients. 
Besides cytogenetic and molecular abnormalities, 
classically, a high WBC count at presentation was considered 
an independent prognostic factor. This illustrated a poor 
outcome in AML, especially for the cytogenetic intermediate 
risk group.13 A subgroup of patients with hyperleucocytosis 
was identified with a shorter rate of survival in these cases.14 
In our study, many laboratory analyses were performed, but 
we chose to combine WBC and blast count for a significant 
difference on our patients survival. Patients were divided 
into groups according to low or high levels of WBC and 
blasts. Patients with values of WBC and blasts >40% had 
much shorter survival than those with low values.
Karyotype abnormalities are probably the most important 
prognostic determinants in AML.15 However, in the literature 
it is reported that half of adult AML patients present with 
a normal karyotype.16 In our study, a proportion of 71 per 
cent presented a normal karyotype and 29 per cent had 
unfavorable cytogenetic abnormalities. In our study, we 
were unable to demonstrate the significance of cytogenetic 
testing due to the small number of patients who benefited 
from cytogenetic examination. Finally, we propose that all 
AML patients should receive cytogenetic examination for a 
better management of AML.
Our single-center study evaluated and confirmed the 
significant predictors of outcome of AML. The age of 
patients, the presence of secondary AML, comorbidities and 
WBC count and blasts were the most important prognostic 
parameters. Furthermore, we demonstrated this in our 
Table 1. Prognosis assessment scheme.
Points Age (years) Secondary AML Comorbidity WBC (cells/mm3) Blasts (%) Cytogenetics
1p <40 - Mild <15000 <40% t (15,17), t (8,21), inv16*
2p 40-59 Present Moderate 15,000-100,000 40-80% Normal karyotype*
3p >59
Present with other 
malignancies
Severe >100,000 >80%* del (7q),+8,del(9q), t(v,11)(v,23)*
*from Medical Literature. Low Risk: 5-6p; Intermediate Risk: 7-9p; High Risk: 10-15p.
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study with the support of significant results of survival 
rates among the different groups of patients.
Conclusion
The understanding of dominant prognostic factors in 
patients with AML is rapidly evolving, but until we find 
more accurate factors, we should clarify the known ones.
This single-center study evaluated the significance of 
pretreatment factors, and found that the age of patients, the 
presence of secondary AML, comorbidities, WBC, blasts and 
cytogenetics were factors which influenced the outcomes 
of survival in patients with AML. Therefore, we propose an 
Assessment Scheme of Prognosis for patients with AML, 
which would be useful to apply a therapeutic regimen and 
to categorize patients into risk groups. Furthermore, we 
can assign patients with AML according to their prognosis, 
in three categories: Low risk, intermediate risk and high 
risk. We included cytogenetic examination with data from 
medical literature, as we were not able to come up with 
our own results, due to our small number of patients who 
received cytogenetic examination. Moreover, we are going 
to check this scheme on a larger patient population to 
demonstrate its significance. On some patients we have 
already evaluated this scheme and we obtained a precise 
prognosis. The scheme works by adding the points if the 
factor is present. For instance, a patient who is aged ≥60 
years (3 points), has AML de novo (1 point), moderate 
comorbidities (2 points), WBC=15000-100.000/mm3 and 
blasts=40-80% (2 points) and an unfavorable chromosomal 
abnormality (3 points) would be classified as high risk. 
Finally, this classification would also help direct the precise 
therapy for this patient.
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lities or normal karyotype
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